美國的低侵入性肥胖手術裝置市場 是由出版商Medtech Insight在2011年03月所出版的。
這份英文市場調查報告書包含232 Pages 價格從美金4750起跳。
在美國約有2億成人（成人人口的68%）被分類成體重過重或是肥胖。肥胖為美國可預防疾病的第2名，每年有將近112,000人因此死亡。肥胖是第2型糖尿病和心臟疾病等的原因，也造成高額的醫療費用。大部分的成人希望能減重，但是利用減肥和運動來減重，有80∼85%的成人無法成功。即使肥胖手術的高費用和併發症的高風險，現在還是僅有1%的肥胖病患接受手術。不過，由於景氣復甦，今後的肥胖手術裝置市場預期在今後5年將大幅擴大，將從2010年的3億4,500萬美元成長到2016年的5億美元，年成長率達6.6%。
本報告，彙整減重治療的未滿足需求和低侵入性減肥手術裝置的概要、產品分析、新興的技術動向與市場的課題等，由下列摘要形式闡述。
報告摘要
第1章 肥胖的臨床概要
- 肥胖的原因
- 卡路里攝取
- 遺傳
- 行動與環境
- 疾病／阻礙與藥劑使用
- 健康上的風險
- 統計
第2章 胃束帶與胃內水球
- 腹腔鏡可調整胃束帶
- 胃內水球
- 市場分析：腹腔鏡可調整胃束帶
- 市場分析：胃內水球
第3章 傳統的非切開式減重技術與裝置
第4章 SINGLE-PORT ACCESS手術
- 單發切開肥胖手術
- 血管擴張內視鏡手術
- 手術件數
- 病患成果
- 經濟與消費者需求
- 產品
第5章 機器人支援低侵入性手術
第6章 嵌入式胃刺激裝置
第7章 企業檔案資料
- Allergan, Inc.
- Covidien PLC
- EndoGastric Solutions, Inc.
- EnteroMedics, Inc.
- GI Dynamics, Inc.
- Intuitive Surgical, Inc.
- Johnson & Johnson
- ReShape Medical, Inc.
- Satiety, Inc.
- Spatz FGIA, Inc.
- TransEnterix, Inc.
- USGI Medical, Inc.PPENDIX COMPANY LI
Abstract
An estimated 200 million adults in the U.S. (a staggering 68% of the adult
population) are categorized as overweight or obese. Obesity is the,
second-leading cause of preventable death in the U.S. resulting in nearly
112,000 deaths annually. The condition is a leading cause of type 2 diabetes,
disability, and heart disease, and is a significant contributor to rising
healthcare costs. Despite the dire need for weight loss in the majority of the
adult population, research has found that diet and exercise alone is
unsuccessful in 80-85% of patients at one year, and only approximately 1% of
the eligible obese population currently undergoes bariatric surgery due to
high cost and high risk of complications. This presents a significant unmet
need for less invasive weight loss treatments. Although more clinical research
is required, minimally invasive bariatric surgical devices and systems may
provide a less costly, safe and effective - and potentially lifesaving -
weight loss alternative.
While current economic conditions continue to restrain market growth, the U.S.
market for minimally invasive bariatric surgical devices is expected to
exhibit relatively strong growth over the next 5 years. Valued at more than
$345 million in 2010, the U.S. minimally invasive bariatric surgical products
market is expected to increase at a healthy compound annual rate of 6.6%, with
sales reaching more than $500 million in 2016.
The market is expected to benefit from increased utilization of laparoscopic
adjustable gastric banding systems and emerging incisionless technologies,
including intragastric balloons and other transorally inserted weight loss
devices, as well as implantable gastric stimulators or vagal blocking systems.
The market is also expected to benefit from growing usage of single-incision
surgery; minimally invasive robotic surgery is also expected to continue to
significantly improve bariatric surgical outcomes.
This dynamic report from Medtech Insight includes analyses of products,
markets, competitors, and emerging technology and opportunities. Covered
topics in this report include laparoscopic adjustable gastric banding (LAGB)
systems; intragastric balloon systems; emerging transorally inserted weight
loss devices; single-incision technologies; minimally invasive robotic
systems; and implantable gastric stimulation/vagal blocking systems.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary
and secondary research among the clinicians, researchers, and competitors in
the marketplace, and draw upon the industry expertise of a network of industry
insiders. Medtech Insight exhaustively corroborates the data as a baseline for
completing forward-looking analysis and providing insight into product,
technology and market evolution.
Report Statistics
- Date Published: March 2011
- Total Number of Pages: 232
- Total Number of Exhibits: 87
- Total Number of Company Profiles: 12
Table of Contents
EXECUTIVE SUMMARY
- i. Causes of Obesity
- ii. Health Risks
- iii. Statistics
- iv. Minimally Invasive Bariatric Surgical Devices Market
- v. Methodology
- Exhibit ES-1: Body Mass Index and Obesity
- Exhibit ES-2: Surgeon General' s Call to Action to Prevent and Decrease
Overweight and Obesity
- Exhibit ES-3: Trends in Overweight, Obesity, and Morbid Obesity, 1988-2008
- Exhibit ES-4: Trends in Overweight, Obesity, and Morbid Obesity, 1960-2008
- Exhibit ES-5: Prevalence of Obesity Among Men, by Race/Ethnicity,
1988-1994 and 2007-2008
- Exhibit ES-6: Prevalence of Obesity Among Women, by Race/Ethnicity,
1988-1994 and 2007-2008
- Exhibit ES-7: Minimally Invasive Bariatric Surgery, Procedure Volumes
Forecast, 2010-2016
- Exhibit ES-8: Minimally Invasive Bariatric Surgical Devices, Combined
Market Forecast, by Segment, 2010-2016
1. CLINICAL OVERVIEW OF OBESITY
- 1.1 Causes of Obesity
- 1.1.1 Calorie Intake
- 1.1.2 Genetics
- 1.1.3 Behavior and Environment
- 1.1.4 Diseases/Disorders and Drug Use
- 1.2 Health Risks
- 1.2.1 Diabetes
- 1.2.2 Cancer
- 1.3 Statistics
- Exhibit 1-1: Body Mass Index and Obesity
- Exhibit 1-2: Surgeon General' s Call to Action to Prevent and Decrease
Overweight and Obesity
- Exhibit 1-3: Comorbidities of Obesity
- Exhibit 1-4: Trends in Overweight, Obesity, and Morbid Obesity, 1988-2008
- Exhibit 1-5: Trends in Overweight, Obesity, and Morbid Obesity, 1960-2008
- Exhibit 1-6: Prevalence of Obesity Among Men, by Race/Ethnicity, 1988-1994
and 2007-2008
- Exhibit 1-7: Prevalence of Obesity Among Women, by Race/Ethnicity,
1988-1994 and 2007-2008
- Exhibit 1-8: 2007, Prevalence of Obesity Among Adults, by State
2. GASTRIC BANDING AND INTRAGASTRIC BALOON SYSTEMS
- 2.1 Laparoscopic Adjustable Gastric Banding
- 2.1.1 Allergan
- 2.1.2 Ethicon Endo-Surgery/Johnson & Johnson
- 2.1.3 Others
- 2.1.3.1 Agency for Medical Innovations
- 2.1.3.2 Cousin Biotech
- 2.1.3.3 Helioscopie
- 2.1.3.4 Medical Innovation Developpement
- 2.2 Intragastric Balloons
- 2.2.1 Allergan
- 2.2.2 Helioscopie
- 2.2.3 Reshape Medical
- 2.2.4 Spatz FGIA
- 2.3 Market Analysis, Laparoscopic Adjustable Gastric Banding
- 2.3.1 Procedure Volumes Forecast
- 2.3.2 Market Forecast
- 2.3.2.1 Market Drivers
- 2.3.2.2 Market Limiters
- 2.3.3 Competitive Analysis
- 2.4 Market Analysis, Intragastric Balloon Systems
- Exhibit 2-1: Risks Associated with Gastric Banding and Abdominal/Bariatric
Surgery
- Exhibit 2-2: 2011, Selected Laparoscopic Adjustable Gastric Banding Devices
- Exhibit 2-3: Allergan' s LAP-BAND AP Adjustable Gastric Banding System
- Exhibit 2-4: Key Benefits and Risks of the LAP-BAND Procedure
- Exhibit 2-5: Excess Weight Loss with the LAP-BAND System Compared to
Roux-en-Y Gastric Bypass at Three Years and Beyond
- Exhibit 2-6: Allergan' s EasyBand Remote Adjustable Gastric Band System
- Exhibit 2-7: Ethicon Endo-Surgery' s Realize Adjustable Gastric Band
- Exhibit 2-8: Pressure Comparison of the Realize Band Balloon with the
LAP-BAND System
- Exhibit 2-9: Comparison of Gastric Banding, Gastric Bypass, and Sleeve
Gastrectomy
- Exhibit 2-10: Effects of the Realize Adjustable Gastric Banding on
Obesity-Related Conditions
- Exhibit 2-11: Ethicon Endo-Surgery' s Realize Band-C Adjustable Gastric Band
- Exhibit 2-12: Agency for Medical Innovations' Soft Gastric Band
- Exhibit 2-13: Cousin Biotech' s Bioring Adjustable Gastric Band
- Exhibit 2-14: Helioscopie' s Heliogast Adjustable Gastric Band
- Exhibit 2-15: Medical Innovation Developpement' s MIDBAND Adjustable
Gastric Band
- Exhibit 2-16: Allergan' s Orbera Managed Weight Loss System
- Exhibit 2-17: Helioscopie' s Heliosphere Intragastric Balloon
- Exhibit 2-18: ReShape Duo Intragastric Balloon System
- Exhibit 2-19: The Spatz Adjustable Balloon System
- Exhibit 2-20: Risks of Intragastric Balloon Placement
- Exhibit 2-21: The Spatz Adjustable Balloon Procedure
- Exhibit 2-22: Laparoscopic Adjustable Gastric Banding, Procedure Volumes
Forecast, 2010-2016
- Exhibit 2-23: Laparoscopic Adjustable Gastric Banding, Market Forecast,
2010-2016
- Exhibit 2-24: 2010, Laparoscopic Adjustable Gastric Banding Systems
Market, Share by Supplier
- Exhibit 2-25: Intragastric Balloon Therapy, Procedure Volumes Forecast,
2010-2016
- Exhibit 2-26: Intragastric Balloon Systems, Market Forecast, 2010-2016
3. TRANSORAL I NCISIONLESS WEIGHT LOSS TECHNOLOGIES AND DEVICES
- 3.1 Selected Products
- 3.1.1 EndoGastric Solutions
- 3.1.2 GI Dynamics
- 3.1.3 Satiety
- 3.1.4 USGI Medical
- Exhibit 3-1: Emerging Trends in Minimally Invasive/Incisionless Surgery
- Exhibit 3-2: EndoGastric Solutions' StomaphyX Transoral Fastener Delivery
System
- Exhibit 3-3: GI Dynamic' s EndoBarrier Gastrointestinal Liner and Procedure
- Exhibit 3-4: GI Dynamic' s EndoBarrier Gastrointestinal Liner Combined with
the EndoBarrier Flow Restrictor
- Exhibit 3-5: Steps of a Transoral Gastroplasty (or TOGA) Procedure
- Exhibit 3-6: USGI Medical' s Incisionless Operating Platform
- Exhibit 3-7: Primary Obesity Surgery, Endolumenal and Repair of Surgery,
Endolumenal
4. SINGLE-PORT ACCESS SURGERY
- 4.1 Single-Incision Bariatric Surgery
- 4.2 Natural Orifice Transluminal Endoscopic Surgery
- 4.3 Procedure Volumes
- 4.4 Patient Outcomes
- 4.5 Economics and Consumer Demand
- 4.6 Selected Products
- 4.6.1 Applied Medical Resources
- 4.6.2 Covidien
- 4.6.3 Ethicon Endo-Surgery/Johnson & Johnson
- 4.6.4 Olympus America/Olympus and Advanced Surgical Concepts
- 4.6.5 TransEnterix
- 4.6.6 USGI Medical
- Exhibit 4-1: Selected Advantages of Single-Port Access Surgery
- Exhibit 4-2: Procedures Employing Single-Port Access
- Exhibit 4-3: Selected Laparoscopic Procedures that Could Benefit from the
Use of Single-Port Access, Procedure Volumes Forecast, 2010-2016
- Exhibit 4-4: Factors Impacting the Adoption of Single-Port Access Surgery
- Exhibit 4-5: Applied Medical Resources' GelPOINT Advanced Access Platform
- Exhibit 4-6: Applied Medical Resources' Premium Disposable Trocar, Kii
GelPort Balloon Trocar, and Universal Seal
- Exhibit 4-7: Covidien' s SILS Port
- Exhibit 4-8: Covidien' s SILS Stitch Articulating Suturing Device
- Exhibit 4-9: Ethicon Endo-Surgery' s ENDOPATH XCEL Bladeless Trocar
- Exhibit 4-10: Ethicon Endo-Surgery' s Single-Site Laparoscopy Access System
- Exhibit 4-11: Olympus America' s Deflectable-Tip EndoEYE Video Laparoscope
- Exhibit 4-12: Advanced Surgical Concepts' TriPort Multiport Access Device
- Exhibit 4-13: Advanced Surgical Concepts' QuadPort Multiport Access Device
- Exhibit 4-14: TransEnterix' s SPIDER Surgical System
- Exhibit 4-15: USGI Medical' s Incisionless Operating Platform
5. ROBOTIC-ASSISTED MINIMALLY INVASIVE SURGERY
- 5.1 Intuitive Surgical
- 5.1.1 The da Vinci Surgical System
- 5.1.1.1 The Da Vinci Gastric Bypass
- 5.1.2 Robotic-Assisted Minimally Invasive Surgery, Market Analysis
- Exhibit 5-1: Selected Procedures Facilitated by the da Vinci Surgical
System
- Exhibit 5-2: Intuitive Surgical' s da Vinci S HD Surgical System
- Exhibit 5-3: Intuitive Surgical' s da Vinci Si HD Surgical System
- Exhibit 5-4: Intuitive Surgical' s EndoWrist Instrument
- Exhibit 5-5: Comparison of the da Vinci Gastric Bypass Procedure with the
Open Surgical Technique
- Exhibit 5-6: Intuitive Surgical' s Revenues and Unit Sales, 2009 and 2010
- Exhibit 5-7: Procedures that Employ Intuitive Surgical' s da Vinci Surgical
System
- Exhibit 5-8: Targeted Procedures for which the da Vinci Surgical System
May Be Employed
- Exhibit 5-9: Robotic-Assisted Minimally Invasive Surgical Systems, Market
Forecast, 2010-2016
6. IMPLANTABLE GASTRIC STIMULATION DEVICES
- 6.1 Selected Products
- 6.1.1 EnteroMedics
- 6.1.2 IntraPace
- 6.1.3 MetaCure
- 6.1.4 Others
- 6.1.4.1 Cyberonics and Ethicon Endo-Surgery/Johnson & Johnson
- 6.1.4.2 Leptos Biomedical
- 6.1.4.3 Medtronic
- 6.1.4.4 St. Jude Medical
- 6.2 Market Analysis
- Exhibit 6-1: 2011, Selected Emerging Implantable Pulse Generators for the
Treatment of Obesity
- Exhibit 6-2: EnteroMedics' Maestro System
- Exhibit 6-3: Overview of EnteroMedics' VBLOC Therapy and Vagus Nerve
Function
- Exhibit 6-4: Potential Benefits and Risks of VBLOC Therapy
- Exhibit 6-5: Comparison of VBLOC Therapy, Laparoscopic Banding, and
Gastric Bypass
- Exhibit 6-6: EMPOWER Study, 24-Month Weight Loss Results
- Exhibit 6-7: VBLOC-DM2 Study, 12-Month Weight Loss Results
- Exhibit 6-8: VBLOC RF2 Study, 24-Month Weight Loss Results
- Exhibit 6-9: IntraPace' s abiliti Gastric Stimulation System
- Exhibit 6-10: MetaCure' s TANTALUS Gastric Stimulation System
- Exhibit 6-11: Medtronic' s Enterra Neurostimulator
- Exhibit 6-12: St. Jude Medical' s Eon Mini Neurostimulator
- Exhibit 6-13: Implantable Gastric Stimulation/VBLOC Therapy Devices, Unit
Sales Forecast, 2010-2016
- Exhibit 6-14: Implantable Gastric Stimulation/VBLOC Therapy Devices,
Market Forecast, 2010-2016
7. COMPANY PROFILES
- 7.1 Allergan, Inc.
- 7.2 Covidien PLC
- 7.3 EndoGastric Solutions, Inc.
- 7.4 EnteroMedics, Inc.
- 7.5 GI Dynamics, Inc.
- 7.6 Intuitive Surgical, Inc.
- 7.7 Johnson & Johnson
- 7.8 ReShape Medical, Inc.
- 7.9 Satiety, Inc.
- 7.10 Spatz FGIA, Inc.
- 7.11 TransEnterix, Inc.
- 7.12 USGI Medical, Inc.PPENDIX COMPANY LI
|
